Quote:On such an informed and educated board such as this, it is easy to lose sight of how much other people/investors do not know. It is only a matter of time until others will learn and invest, just like I did at one time. The tortoise will beat the hare in this race.
I've been long since 2019 (first buy at .89) but I am not sure I could give a convincing answer to a prospective buyer asking why the clinical trials announced by Jay should be a success. Yesterday I asked this question myself after reading one of the articles that mentions LL, thanks to the links one of the board members published yesterday. Here's the quote
Quote:Maraviroc is an oral CCR5 antagonist. In a phase I study, patients with metastatic mismatch-repair-proficient and microsatellite stable (pMMR/MSS) colorectal cancer (mCRC) received combination therapy with pembrolizumab (anti-PD-1) and maraviroc. The mPFS based on irRECIST was 2 months (95% CI, 2–3), and the mOS was 9 months (95% CI, 6–20).142 Leronlimab is a humanized IgG4κ antibody that blocks the CCR5 receptor. In a pooled analysis of three clinical drug studies (phase Ib/II dose escalation (NCT03838367), compassionate use (NCT04313075), and basket study (NCT04504942)), metastatic triple-negative breast cancer (mTNBC) patients were treated with Leronlimab. The results showed that at 12 months, the mPFS was 3.8 months (95% CI, 2.3–6.2), and the mOS was 6.6 months (95% CI, 4.9%–12%).143/quote]
How do I, who never cared to take BIO 101, know having read this passage that out of these two CCR5 antagonists I should invest in the unapproved LL rather in in the approved maraviroc? The worst problem we have in encouraging new investments is the absence of plain language interpretations of our clinical trials results for laymen like myself. I think I could say something why results of CD 10 and 12 were so promising despite of not reaching the statistical pass but only because I benefited from the knowledgeable board members discussing them. But I am in almost complete dark as to how the results of other previous LL trials merit our present high hopes re the planned colorectal, oncology, and other trials and studies. In plain language!!!
10
CytoDyn Inc (CYDY) Stock Research Links
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
